basiliximab (Rx)

Brand and Other Names:Simulect
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

powder for injection

  • 10mg
  • 20mg
more...

Prophylaxis of Renal Transplant Rejection

20 mg IV within 2 hr prior to transplant surgery, THEN

20 mg IV 4 days after transplant

Withhold second dose if complications (severe hypersensitivity, or graft loss) occur after first dose

Used in regimen containing cyclosporine and corticosteroids

Acute Cardiac Transplant Rejection Prophylaxis (Unlabeled)

20 mg IV on day of transplant surgery, THEN

20 mg IV 4 days after transplant

Withhold second dose if complications (severe hypersensitivity, or graft loss) occur after first dose

Used in regimen containing cyclosporine and corticosteroids

Acute Liver Transplant Rejection Prophylaxis (Unlabeled)

20 mg IV within 6 hr of organ reperfusion, THEN

20 mg IV 4 days after transplant

Withhold second dose if complications (severe hypersensitivity, or graft loss) occur after first dose

Used in regimen containing cyclosporine and corticosteroids

Treatment of Refractory Acute GVHD (Unlabeled)

20 mg IV on day of organ reperfusion, THEN

20 mg IV 4 days after transplant

May repeat for recurrent acute GVHD

Dosage Forms & Strengths

powder for injection

  • 10mg
  • 20mg
more...

Prophylaxis of Renal Transplant Rejection

<35 kg: 10 mg IV within 2 hr prior to transplant surgery, THEN 10 mg IV 4 days after transplant

>35 kg: Administer as in adults; 20 mg IV within 2 hr prior to transplant surgery, THEN, 20 mg IV 4 days after transplant

Used in regimen containing cyclosporine and corticosteroids

Next:

Interactions

Interaction Checker

and basiliximab

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Note: Difficult to distinguish from adverse events associated with organ transplantation

            >10%

            Abdominal pain

            Acne

            Anemia

            Constipation

            Diarrhea

            Dyspepsia

            Fever

            Headache

            Hypo- or hyperkalemia

            Hyperglycemia

            Hyperuricemia

            Hypophosphatemia

            Hypercholesterolemia

            Hypertension

            Insomnia

            Nausea

            Pain

            Peripheral edema

            Tremor

            UTI

            Viral infection

            Vomiting

            Wound healing complications

            1-10%

            Acidosis

            Agitation

            Angina

            Anxiety

            Arthralgia

            Arrhythmia

            Atrial fibrillation

            Bronchitis

            Bronchospasm

            Cardiac failure

            Chest pain

            Cough

            Cyst

            Dehydration

            Depression

            Dizziness

            Edema

            Fatigue

            Flatulence

            Gingival hyperplasia

            GI hemorrhage

            Hematoma

            Hemorrhage

            Hypotension

            Hypomagnesemia

            Hyponatremia

            Hyper or hypocalcemia

            Hyperlidpidemia

            Hypertrichosis

            Increased glucocorticoids

            Infections

            Neuropathy

            Pruritus

            Rash

            Leukopenia

            Lymphoproliferative disorders

            Oliguria

            Polycythemia

            Pulmonary edema

            Renal function abnormalities

            Skin ulceration

            Stomatitis

            Tachycardia

            Thrombocytopenia

            Thrombosis

            Urinary frequency

            Urinary retention

            Vision abnormalities

            Previous
            Next:

            Warnings

            Black Box Warnings

            Should be prescribed only by physicians who have experience with immunosuppression in organ transplant recipients and can provide necessary follow-up and appropriate monitoring

            Contraindications

            Hypersensitivity

            Warnings

            Development of human antimurine antibodies reported for murine products

            Risk of developing lymphoproliferative disorders may increase with immunosuppressive therapy

            Immunosuppressive therapy may increase risk of opportunistic infection

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: Unknown whether excreted in milk; because of the potential for adverse reactions, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Interleukin-2 receptor antagonist for activated T lymphocytes (pathway responsible for activating cell-mediated allograft rejection)

            Pharmacokinetics

            Peak plasma time: 30 min

            Concentration: 7.1 mg/L

            Vd: 8.6 L (adults); 7.8 ± 5.1 (adolescents); 4.8 ± 2.1 L (children)

            Half-Life: 7.2 days (adults); 9.1 days (adolescents); 9.5 days (children)

            Metabolism: Unknown

            Clearance: 41 mL/hr

            Excretion: Unknown

            Duration: 36 days

            Previous
            Next:

            Administration

            IV Preparation

            Reconstitute vials with 5 mL SWI

            Dilute reconstituted contents in 50 mL NS or D5W

            IV Administration

            For central or intravenous administration only

            Infuse over 20-30 min

            Storage

            Store vials under refrigeration 2-8°C (36-46°F)

            Reconstituted vials are stable under refrigeration for 24 hr, but only 4 hr at RT

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous